	US 12,458,710 B2
	Astatine solution and method for producing same
Yoshifumi Shirakami, Suita (JP); Tadashi Watabe, Suita (JP); Kazuko Kaneda, Suita (JP); Eku Shimosegawa, Suita (JP); Atsushi Shinohara, Suita (JP); and Jun Hatazawa, Suita (JP)
Assigned to OSAKA UNIVERSITY, Suita (JP)
Filed by OSAKA UNIVERSITY, Suita (JP)
Filed on May 15, 2023, as Appl. No. 18/317,224.
Application 18/317,224 is a continuation of application No. 16/958,147, granted, now 11,684,683, previously published as PCT/JP2018/048442, filed on Dec. 28, 2018.
Claims priority of application No. 2017-255109 (JP), filed on Dec. 29, 2017.
Prior Publication US 2023/0302169 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/12 (2006.01); A61K 47/22 (2006.01)

CPC A61K 51/121 (2013.01) [A61K 47/22 (2013.01)]

20 Claims

1. A method for treating or diagnosing a thyroid cancer or a thyroid cancer metastatic lesion, comprising administering a therapeutically effective amount of an aqueous solution, an ethanol solution, or an aqueous ethanol solution, each comprising ²¹¹At⁻ at a radiochemical purity of not less than 90% as an active ingredient and a reducing agent selected from the group consisting of ascorbic acid and a salt of ascorbic acid, wherein the aqueous solution, ethanol solution, or aqueous ethanol solution is produced by a method comprising a step of adding a reducing agent selected from the group consisting of ascorbic acid and a salt of ascorbic acid to an aqueous solution, an ethanol solution, or an aqueous ethanol solution, each comprising an impurity derived from ²¹¹At obtained by a nuclear reaction, wherein the reducing agent is added at a final concentration of 0.5-30 wt % with respect to the aqueous solution, ethanol solution, or aqueous ethanol solution.